Biotechnology Venture Capital Law In Russia.

1. Introduction

Biotechnology venture capital law in Russia concerns the legal framework governing investments in innovative biotechnology enterprises, pharmaceutical companies, genetic-engineering businesses, medical-device manufacturers, vaccine developers, bioinformatics companies, and life-science research ventures.

Venture capital (VC) is a form of high-risk investment in businesses with significant growth potential. Biotechnology companies frequently require substantial funding because scientific research, laboratory development, clinical trials, regulatory approvals, intellectual-property protection, and commercialisation can take several years.

Russia does not have one comprehensive statute exclusively regulating biotechnology venture capital. Instead, the applicable legal framework combines:

Civil Code of the Russian Federation.

Federal Law No. 39-FZ of 22 April 1996 on the Securities Market.

Federal Law No. 156-FZ of 29 November 2001 on Investment Funds.

Federal Law No. 335-FZ of 28 November 2011 on Investment Partnerships.

Federal Law No. 259-FZ of 2 August 2019 on Digital Financial Assets.

Federal Law No. 127-FZ of 26 October 2002 on Insolvency (Bankruptcy).

Federal Law No. 127-FZ of 23 August 1996 on Science and State Scientific and Technical Policy.

These laws collectively govern investment structures, investor rights, fundraising, corporate ownership, financial instruments, intellectual property, insolvency, and the commercialisation of scientific research.

2. Legal framework governing biotechnology venture capital

A. Civil Code of the Russian Federation

The Civil Code provides the fundamental legal basis for venture capital transactions.

Relevant provisions include:

Article 66: Legal status of commercial companies and partnerships.

Articles 87–94: Limited liability companies and their legal framework.

Articles 96–104: Joint-stock companies and related corporate rules.

Articles 1041–1054: Simple partnership agreements.

Articles 1225 onwards: Intellectual property rights.

Articles 1345–1407: Patent rights and protection of inventions.

Application to biotechnology:

Suppose a Russian biotechnology startup develops a new gene-editing technology. A venture capital investor contributes RUB 100 million in exchange for a 25% ownership interest.

The investment agreement should specify:

The amount and timing of investment.

The investor's equity ownership.

Voting and governance rights.

Ownership of patents and research results.

Confidentiality obligations.

Restrictions on transferring shares.

Exit arrangements.

Remedies for breach of contractual obligations.

The Civil Code provides the foundation for enforcing these contractual and proprietary rights.

rospatent.gov.ru+1

 

B. Federal Law No. 335-FZ of 28 November 2011 – Investment Partnership

This is one of the most important statutes for Russian venture capital investment.

The law establishes a contractual structure through which investors pool resources to finance investment projects.

Under this arrangement:

Managing partners administer investment activities.

Investor partners contribute capital.

The partnership agreement establishes the parties' rights and obligations.

Investment property is held and administered under the statutory partnership framework.

Profits and losses are allocated according to the agreement and applicable law.

Unlike an LLC or joint-stock company, an investment partnership is not itself a separate legal entity.

Biotechnology application:

Several investors may establish an investment partnership to finance:

Pharmaceutical research.

Vaccine development.

Genetic-engineering startups.

Stem-cell research.

Agricultural biotechnology.

Biotechnology manufacturing facilities.

The agreement should clearly establish capital commitments, contribution deadlines, management authority, investment restrictions, distributions, and withdrawal procedures.

A significant issue arises when an investor promises to contribute capital but subsequently refuses to pay a capital call. The enforceability of that commitment depends on the agreement and applicable law.

cis-legislation.com+1

 

C. Federal Law No. 156-FZ of 29 November 2001 – Investment Funds

This law regulates the formation and management of investment funds in Russia.

It is relevant to biotechnology venture capital because investment funds can pool money from multiple investors and invest in innovative businesses.

Important features include:

Collective investment arrangements.

Trust management of investment assets.

Management-company supervision.

Custody and accounting of fund property.

Protection of investors' interests.

A closed-end mutual investment fund may be used as a vehicle for holding investments in innovative companies, subject to the statutory investment restrictions.

Example: A venture fund collects capital from institutional investors and invests in a Russian biotechnology company developing recombinant vaccines.

The fund manager must comply with investment-fund legislation and applicable Central Bank requirements.

cis-legislation.com+1

 

D. Federal Law No. 39-FZ of 25 February 1999 – Investment Activities

This legislation establishes the legal and economic basis for investment activities involving capital investments in Russia.

It recognises investments in money, securities, property rights and other assets having monetary value.

For biotechnology businesses, it is relevant to investments in:

Laboratory infrastructure.

Pharmaceutical manufacturing facilities.

Biotechnological equipment.

Research facilities.

Industrial-scale production infrastructure.

It also provides a framework for protecting the interests of investment participants.

cis-legislation.com+1

 

E. Federal Law No. 244-FZ of 28 September 2010 – Skolkovo Innovation Centre

The Skolkovo legislation is relevant to the commercialisation of scientific research and innovative technologies.

It provides an institutional framework for supporting research and the commercialisation of research results.

Biotechnology startups may benefit from innovation-centre participation where they satisfy the applicable eligibility and project requirements.

Potential activities include:

Biomedical research.

Pharmaceutical innovation.

Medical technology development.

Genetic engineering.

Bioinformatics.

Innovative diagnostic systems.

The legislation is particularly relevant where a venture capital investor finances a research project connected with the Skolkovo innovation ecosystem.

cis-legislation.com+1

 

F. Federal Law No. 216-FZ of 29 July 2017 – Innovative Scientific and Technological Centres

This law provides a framework for innovative scientific and technological centres designed to facilitate research, development and commercialisation.

Such centres can support collaboration between universities, research institutions, businesses and investors.

For biotechnology, this framework can facilitate the transition from laboratory research to commercial production.

cis-legislation.com

3. Legal structure of biotechnology venture capital transactions

Russian biotechnology venture capital transactions may use several organisational structures.

Investment structureLegal purpose
Limited liability company (LLC)Equity investment in a startup
Joint-stock company (JSC)Share-based investment and ownership
Investment partnershipPooling capital from several investors
Closed-end mutual investment fundCollective investment and portfolio management
Business partnershipFinancing innovative commercial projects
Direct investment agreementContractual financing of a biotechnology enterprise

The choice depends on the investment size, investor profile, management arrangements, tax considerations, and intended exit strategy.

Important distinction: A financing agreement does not automatically give an investor ownership of a biotechnology company's patents. Patent ownership, licensing and assignment must be addressed separately.

4. Venture capital financing stages in biotechnology

Biotechnology companies generally require different financing arrangements at different development stages.

Biotechnology venture capital lifecycle

Seed financing

Funding initial scientific research, laboratory experiments, research personnel and proof-of-concept development.

Series A financing

Funding technology development, preclinical studies, patent applications and prototype development.

Series B financing

Funding clinical development, manufacturing preparation and regulatory submissions.

Growth financing

Funding commercial production, distribution networks and market expansion.

Exit financing

Investors realise returns through acquisition, share transfers, strategic transactions or public offerings.

Russian law does not create a separate statutory licensing regime for each venture capital financing round. The legal obligations depend on the transaction structure, the company's activities and the applicable regulatory requirements.

5. Intellectual property protection in biotechnology investments

Intellectual property is one of the most valuable assets of biotechnology startups.

Investors may finance a company because it owns or controls:

Genetic-engineering technologies.

Pharmaceutical formulations.

Recombinant proteins.

Vaccine platforms.

Diagnostic technologies.

Biotechnology manufacturing processes.

Bioinformatics software.

Proprietary research databases.

Part IV of the Civil Code provides the main framework for protecting intellectual property.

Important legal issues

A. Patent ownership

The investor must determine whether the startup actually owns the patents it claims to own.

B. Employee inventions

Research employees may develop patentable inventions during employment. The legal allocation of rights between the employee and employer must be examined.

C. University research

Where university researchers develop biotechnology inventions, ownership may depend on employment arrangements, research agreements, funding conditions and statutory rules.

D. Technology licensing

A startup may obtain investment based on a licence rather than ownership of the underlying technology. Investors must examine the licence's duration, exclusivity, territory, sublicensing rights and termination provisions.

E. Trade secrets

Experimental methods, manufacturing processes, unpublished research and proprietary biological production information may qualify for trade-secret protection if the statutory requirements are satisfied.

Why this matters: If a biotechnology startup loses its essential patent or technology licence, the economic value of the investor's equity may decline substantially.

6. Government regulation and investor protection

Biotechnology venture capital investors must consider regulatory approvals in addition to financial and corporate requirements.

Regulatory areaPrincipal legal framework
Pharmaceutical productsFederal Law No. 61-FZ of 12 April 2010
Medical devicesFederal Law No. 323-FZ of 21 November 2011 and applicable subordinate regulations
Biomedical cell productsFederal Law No. 180-FZ of 23 June 2016
Genetic engineeringFederal Law No. 86-FZ of 5 July 1996
Personal and genetic dataFederal Law No. 152-FZ of 27 July 2006
InsolvencyFederal Law No. 127-FZ of 26 October 2002
CompetitionFederal Law No. 135-FZ of 26 July 2006

An investor should not assume that financing a biotechnology startup authorises the startup to manufacture or market a pharmaceutical or biological product.

Regulatory approval, clinical-trial permissions, manufacturing requirements and other applicable authorisations remain necessary.

7. Important Russian case laws relevant to biotechnology venture capital

An important qualification is necessary: Russia does not have a large body of published judgments specifically addressing venture capital investments in biotechnology companies. Therefore, the following decisions are relevant through investment-contract, pharmaceutical patent and intellectual-property principles. They should not be misrepresented as direct biotechnology venture capital judgments.

Case 1: Nativa LLC v. Celgene Corporation

Pharmaceutical patent precedent

Case number: A40-71471/2017

Court: Moscow Arbitration Court and subsequent appellate and intellectual-property proceedings.

Subject: Compulsory licensing of pharmaceutical patent rights.

Relevant legislation: Article 1362 of the Russian Civil Code.

Facts:

Nativa sought a compulsory, non-exclusive licence concerning Celgene's patent relating to lenalidomide, a pharmaceutical substance used in cancer treatment.

The dispute concerned the relationship between patent exclusivity, dependent inventions and the ability of another pharmaceutical company to commercialise a product.

Legal significance:

The dispute illustrates that patent exclusivity is subject to statutory limitations and that compulsory licensing can become relevant when the legal requirements are satisfied.

Importance for venture capital:

A biotechnology venture capital investor must assess whether the startup's technology depends on patents owned by another company. Patent freedom-to-operate analysis is particularly important before investing in pharmaceutical research and development.

Law Gratis+1

Case 2: Sugen LLC and Pharmacia & Upjohn v. Nativa LLC

Pharmaceutical innovation precedent

Case number: A40-166505/2017

Subject: Sunitinib patent infringement and compulsory licensing.

Relevant legislation: Articles 1252 and 1362 of the Russian Civil Code.

Facts:

Sugen and Pharmacia & Upjohn brought proceedings concerning alleged unauthorised use of patented technology in connection with Nativa's sunitinib pharmaceutical product.

Nativa filed a counterclaim seeking a compulsory licence.

The proceedings involved the competing interests of patent holders and pharmaceutical manufacturers.

The matter went through judicial review, and a further Supreme Court challenge was refused on 20 February 2020.

Legal significance:

The dispute demonstrates the importance of balancing patent protection with the statutory conditions for compulsory licensing.

Importance for venture capital:

Investors funding biotechnology and pharmaceutical startups should investigate:

Existing patent rights.

Third-party licensing arrangements.

Patent infringement risks.

Compulsory licensing exposure.

Commercialisation restrictions.

Law Gratis+1

Case 3: Investment Partnership Capital Commitment – Russian Judicial and Academic Practice

Directly relevant investment structure

Research: Maxim A. Korostelev.

Publication: Legal Nature of the Capital Commitment in Investment Partnership Agreement and Recovery of a Non-Performed Capital Call in the Investment Partnership.

Journal: Russian Justice, 2024, No. 12, pages 41–50.

Subject: Enforcement of capital commitments under Federal Law No. 335-FZ.

Legal issues examined:

Whether an investor's commitment to contribute capital is legally enforceable.

Whether a managing partner can recover unpaid capital contributions.

Whether contributed capital can be returned.

How the investment partnership agreement affects the parties' obligations.

Significance for biotechnology venture capital:

Suppose three investors agree to contribute RUB 300 million to a biotechnology investment partnership. One investor promises RUB 100 million but refuses to make the required payment.

The managing partner may need to pursue contractual recovery.

The legal outcome depends on the partnership agreement, the capital-call provisions and the applicable statutory framework.

This publication is a legal analysis of legislation and judicial practice, not itself a court judgment.

RCSI Journals Platform+1

 

Case 4: Axelpharm pharmaceutical patent and competition disputes

Case numbers: A40-264483/2024 and A40-315385/2024.

Subject: Pharmaceutical patents, generic products and unfair competition.

Regulatory authority: Federal Antimonopoly Service of Russia.

These proceedings concerned pharmaceutical products involving axitinib and osimertinib.

They illustrate the relationship between patent rights, pharmaceutical market entry and competition-law enforcement.

Venture capital significance:

Investors financing biosimilars, recombinant medicines and biotechnology-derived pharmaceuticals should examine patent expiry dates, third-party rights and competition-law exposure before committing capital.

These are pharmaceutical-sector disputes, not direct venture capital cases.

Law Gratis+1

 

8. Foreign venture capital investment in Russian biotechnology

Foreign investment raises additional legal issues.

The principal legislation includes:

Federal Law No. 160-FZ of 9 July 1999 on Foreign Investments in the Russian Federation.

Federal Law No. 57-FZ of 29 April 2008 on Foreign Investments in Business Entities of Strategic Importance for National Defence and State Security.

Federal Law No. 173-FZ of 10 December 2003 on Currency Regulation and Currency Control.

Important considerations:

A. Foreign ownership

Foreign investors must examine restrictions on acquiring interests in companies carrying out activities subject to strategic-investment screening.

B. Biological research security

Where a company conducts activities involving legally protected biological materials, dangerous biological agents or other sensitive research, additional regulatory restrictions may apply.

C. Cross-border technology transfer

Transfers of biotechnology patents, laboratory equipment, technical documentation and research materials may be subject to export-control, sanctions and other applicable restrictions.

D. Currency and payment restrictions

Foreign investment transactions must comply with Russian currency-control legislation and applicable financial regulations.

E. International sanctions

Investors must independently assess applicable sanctions, banking restrictions, investment prohibitions and counterparty risks.

The legal structure of a foreign investment should therefore be examined before funds are transferred or ownership interests are acquired.

9. Taxation of biotechnology venture capital

Tax considerations are important because biotechnology research frequently produces losses during its initial development years.

Relevant areas include:

Corporate profits tax.

Tax treatment of dividends.

Taxation of investment fund income.

Tax treatment of intellectual-property licensing.

VAT treatment of biotechnology products and services.

Tax treatment of research and development expenditure.

Russia's Tax Code provides the principal framework.

Eligible innovation businesses may also benefit from specific tax incentives, including applicable Skolkovo-related benefits, subject to statutory conditions.

An investor should distinguish between:

Equity investment.

Shareholder loans.

Convertible financing arrangements.

Royalty-based financing.

Research and development contracts.

These instruments may produce different tax consequences.

10. Bankruptcy and investor protection

Biotechnology companies are particularly vulnerable to insolvency because research projects can require years of financing before commercial returns become available.

Federal Law No. 127-FZ of 26 October 2002 governs insolvency and bankruptcy.

Important risks include:

Failure to complete clinical development.

Loss of major research contracts.

Inability to obtain regulatory approval.

Withdrawal of venture capital funding.

Loss of essential intellectual-property rights.

Failure to pay employees and suppliers.

Example:

A Russian biotechnology startup receives RUB 500 million to develop a new vaccine. The clinical development programme fails, and the company cannot repay its creditors.

The bankruptcy process may involve the realisation of assets, creditor claims and disputes over intellectual-property ownership.

Investors should ensure that patent assignments, licensing agreements, security interests and shareholder arrangements are properly documented.

11. Major legal challenges in Russian biotechnology venture capital

Legal challengePotential consequence
Scientific uncertaintyFailure to achieve research objectives
Patent ownership disputesLoss of exclusive technology rights
Regulatory delaysPostponement of commercialisation
Capital-call defaultsInsufficient funding
Foreign investment restrictionsRestrictions on ownership or control
Clinical-trial failureFinancial losses
Trade-secret leakageLoss of competitive advantage
BankruptcyLoss or reduction of investment value
Sanctions and export controlsDisruption of international financing
Weak exit opportunitiesDifficulty realising investor returns

12. Recommendations for strengthening biotechnology venture capital regulation in Russia

Several legal and institutional reforms could improve the financing environment.

1. Specialised biotechnology investment framework

A clearer framework could address the distinctive risks of investing in pharmaceutical, genetic-engineering and medical biotechnology companies.

2. Standardised venture capital agreements

Standard documentation could clarify capital commitments, investor rights, management responsibilities and exit arrangements.

3. Stronger intellectual-property due diligence

Investors should have reliable procedures for verifying patent ownership, employee inventions, research agreements and licensing rights.

4. Clinical research investment safeguards

Investment agreements should establish procedures for handling research delays, failed experiments, adverse events and regulatory rejection.

5. Improved university-industry collaboration

Clearer rules concerning ownership of university-developed inventions could facilitate commercialisation and private investment.

6. Greater transparency in investment partnerships

Clear reporting requirements and enforceable capital-call procedures could improve investor confidence.

7. Better protection of minority investors

Corporate governance arrangements should provide appropriate information rights, voting protections and remedies for misconduct.

13. Conclusion

Biotechnology venture capital law in Russia is based on a combination of corporate, investment, contractual, intellectual-property, pharmaceutical and insolvency legislation.

Federal Law No. 335-FZ on Investment Partnerships and Federal Law No. 156-FZ on Investment Funds are particularly significant for structuring venture capital funds. The Civil Code provides the foundation for corporate ownership, contractual obligations and intellectual-property protection.

Russian pharmaceutical patent disputes, particularly Nativa v. Celgene and Sugen and Pharmacia & Upjohn v. Nativa, demonstrate why patent rights and compulsory licensing must be considered when financing biotechnology businesses.

However, the absence of an extensive body of biotechnology-specific venture capital judgments means that investors must rely substantially on general commercial and investment law.

Ultimately, effective biotechnology venture capital regulation requires a balance between investor protection, scientific innovation, intellectual-property rights, patient safety and the commercialisation of research.

14. Important legal references and research sources

Federal Law No. 335-FZ – Investment Partnership.

Federal Law No. 156-FZ – Investment Funds.

Civil Code of the Russian Federation.

Federal Law No. 244-FZ – Skolkovo Innovation Centre.

Federal Law No. 216-FZ – Innovative Scientific and Technological Centres.

Russian Justice – Capital Commitments in Investment Partnerships (2024).

HSE Research – Legal Issues of Structuring Venture Investment Transactions (2025).

Academic note: This is a general legal research explanation, not an exhaustive account of Russian legislation as amended on 18 November 2026. The current consolidated Russian statutory texts and full court judgments should be checked before relying on any provision or precedent in litigation or an actual investment transaction.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT